2022 INVICTUS TRIAL Rivaroxaban in rheumatic heart disease associated atrial fibrillation (AF) Prospective, parallel group, open-label, randomized clinical trial d e Objective: To evaluate Rivaroxaban compared with Vitamin K antagonist among patients with rheumatic heart disease & atrial fibrillation antagonis 4531 patients Adults at least 18 years of age with rheumatic heart disease; AF or […]